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Abstract: Patients with COPD and other chronic respiratory diseases are especially vulnerable 
to viral and bacterial pulmonary infections, which are major causes of exacerbations, hospital-
ization, disease progression, and mortality in COPD patients. Effective vaccines could reduce 
the burden of respiratory infections and acute exacerbations in COPD patients, but what is the 
evidence for this? This article reviews and discusses the existing evidence for pneumococcal 
vaccination efficacy and its changing role in patients with chronic respiratory diseases, especially 
COPD. Specifically, the recent Community-Acquired Pneumonia Immunization Trial in Adults 
(CAPITA) showed the efficacy of pneumococcal conjugate vaccine in older adults, many of 
whom had additional risk factors for pneumococcal disease, including chronic lung diseases. 
Taken together, the evidence suggests that pneumococcal and influenza vaccinations can prevent 
community-acquired pneumonia and acute exacerbations in COPD patients, while pneumococcal 
vaccination early in the course of COPD could help maintain stable health status. Despite the need 
to prevent pulmonary infections in patients with chronic respiratory diseases and evidence for 
the efficacy of pneumococcal conjugate vaccine, pneumococcal vaccine coverage and awareness 
are low and need to be improved. Respiratory physicians need to communicate the benefits of 
vaccination more effectively to their patients who suffer from chronic respiratory diseases.
Keywords: COPD, COPD exacerbation, infection, pneumococcal vaccine
Introduction
Patients with chronic respiratory diseases (CRDs), especially those with COPD, exhibit 
altered lung defenses and frequently have multiple comorbidities, which include cardiovas-
cular disease, diabetes, metabolic syndrome, chronic anemia, osteoporosis, depression, and 
cancer.1–3 Such adverse conditions make these patients especially vulnerable to viral and 
bacterial pulmonary infections, which are major causes of exacerbations, hospitalization, 
and disease progression.1,4,5 Pneumonic infections in COPD patients have a major impact 
on morbidity, mortality, and health-care costs.6,7 Since vaccines are among the most effec-
tive means of preventing infectious diseases and their consequences, preventing pulmonary 
infections in COPD patients through vaccination could reduce the burden of COPD and its 
complications, as well as further declines in patient health. For many years, pneumococ-
cal vaccination in adults has relied primarily on polysaccharide vaccines. More recently, 
however, a large study demonstrated the efficacy of pneumococcal conjugate vaccine 
(PCV) in older adults (Community-Acquired Pneumonia Immunization Trial in Adults 
[CAPITA]), in which many of the participants had additional risk factors for pneumococcal 
disease.8 Following these new developments, a symposium was held at the 2016 European 
Respiratory Society International Congress (September 5, 2016, London, UK) to examine 
and discuss the changing role of pneumococcal vaccination in patients with CRD, espe-
cially COPD. One major aim of these discussions was to document whether vaccination 
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with PCV should be included among other strategies known 
to benefit COPD patients, such as smoking cessation, respira-
tory therapy, trigger avoidance, and influenza vaccination, 
to reduce the risk of exacerbations and respiratory events.
Pneumococcal diseases in patients 
with chronic respiratory diseases
The global burdens of respiratory diseases remain among 
the highest of all diseases and the most frequent causes of 
death.9,10 COPD and lower respiratory tract infections (LRTIs) 
are the third- and fourth-leading causes of death, respectively, 
after heart disease and stroke,9,11 with ~55% of all LRTI deaths 
attributable to pneumococcal pneumonia.10 In Europe, pneu-
monia is the leading cause of respiratory hospitalizations and 
the second leading cause of death due to respiratory disease 
after lung cancer.12 The situation is compounded by the nearly 
23 million Europeans with moderate–severe COPD who 
account for 1.1 million hospitalizations and 150,000 deaths 
each year.12 COPD is frequently associated with comorbidi-
ties that contribute greatly to patient mortality. Among these, 
coronary artery disease and congestive heart failure play a 
major role.2 Hospitalizations and deaths due to COPD can be 
expected to rise in the future as the disease progresses in the 
17 million additional persons in the EU, who are estimated 
to be living with mild-stage COPD.12 Currently, pneumonia, 
COPD, and asthma account for 55.7% of respiratory hospital 
admissions and 47.3% of respiratory deaths in the EU.12
Patients with COPD, other CRDs, or other underlying 
chronic conditions are at high risk of community-acquired 
pneumonia (CAP), which imposes a substantial disease burden 
on the European population. Each year, there are an estimated 
3.37 million cases of CAP, almost a third of which require 
hospitalization.12 A retrospective cohort analysis of health-
care claims in the US determined the risk of pneumococcal 
pneumonia to be 2.7 times higher in adults 65 years old 
compared to adults 50−64 years old (Figure 1).13 In general, 
the incidence of pneumococcal pneumonia increased after 
the age of 65 years and was severalfold higher in persons of 
all ages living with chronic diseases, such as diabetes, heart 
disease, asthma, or lung disease, or with underlying condi-
tions, such as smoking or alcoholism, compared to those with 
no known risk conditions. Among adults 65 years old, the 
incidence of pneumococcal pneumonia was 7.7-fold higher 
in persons with CRD compared to those without comorbidity 
(Figure 1). Further, incidence increased exponentially in 
patients who had multiple comorbidities (“risk stacking”). 
In patients with three at-risk conditions, incidence was 9–16 
times higher than in healthy adults without any known risk 
factors and twice as high as in immunocompromised patients, 
who are considered to be at high risk.13
The prevalence of chronic conditions that put people at 
risk is also high, as shown in another US study in which 32.1% 
of adults 45−64 years old and 61.6% of adults 65 years of 
age had at least two chronic conditions and were considered 
at high risk of CAP.14 As the mean age of the population 
continues to increase, the prevalence of persons with multiple 
chronic conditions is also expected to rise.14 In Europe, the 
incidence of CAP was found to be more than 20-fold higher 
in persons with COPD (22.4 per 1,000 person-years) than in 
the general population (1.07−1.2 per 1,000 person-years), 
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Figure 1 Incidence of pneumococcal pneumonia in adults with underlying conditions in the US, 2007–2010.
Notes: By age group and chronic condition. The retrospective cohort analysis utilized health-care claims data from 2007 through 2010 to compare the rates of pneumococcal 
disease among persons with certain chronic conditions versus their age-matched healthy counterparts. The databases included medical claims (ie, facility and professional 
services) and outpatient pharmacy claims from private US health plans. Data from Shea et al.13
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with the incidence dramatically higher in persons with severe 
COPD (forced expiratory volume in 1 second [FEV
1
] 50% 
of expected).15,16 In Sweden, the risk of severe/invasive 
pneumococcal disease (IPD) was fivefold higher in persons 
with COPD or pulmonary fibrosis and twice as high in 
persons with asthma than in the general population.17
COPD patients may be more susceptible to respiratory 
infections, because their mucociliary clearance mechanisms 
are impaired, and production of the specific cell adhesion 
molecules that mediate attachment of bacteria and viruses 
is increased in their airways. Expression of platelet adhesion 
factor receptor (a cell adhesion molecule for Streptococcus 
pneumoniae and untypable Haemophilus influenza) and more 
recently ICAM1 (a cell adhesion molecule for rhinovirus) 
have been found to be significantly elevated in COPD patients 
and smokers compared to normal controls.18,19 Elevated 
levels of these proteins may increase the risk of respiratory 
infection and bacterial colonization. In addition, certain treat-
ments, such as inhaled corticosteroids, can further increase 
the risk of pneumonia in COPD patients. This risk appears 
to increase with the dose of the drug, regardless of disease 
severity, although it does not appear to be associated with a 
concomitant increase in mortality.20
Preventing exacerbations in COPD patients is a major 
treatment objective. Among the predominant triggers of 
exacerbations are LRTI, environmental contaminants, pol-
lution, and poor compliance with pulmonary rehabilitation 
regimes or with long-term oxygen therapy.21 However, 
approximately two-thirds of exacerbations are associated 
with bacterial or viral LRTI or bacterial colonization of the 
lungs,1,5,22,23 and the spectrum of microorganisms associated 
with these infections appears to vary with disease severity.24 
In a study of hospitalized COPD patients, Streptococcus 
spp. were more prevalent in patients with less severe 
airway obstruction, whereas Haemophilus spp. were more 
prevalent in moderate disease and Enterobacteriaceae and 
Pseudomonas spp. in severe disease.24 This finding suggests 
that pneumococcal vaccination should be envisaged particu-
larly in patients with mild airflow obstruction.
Although there has been some debate on whether pneu-
monia should be considered a cause or differential diagnosis 
of acute exacerbation of COPD (AECOPD), another impor-
tant observation is that pneumonic AECOPD tends to be more 
severe than nonpneumonic AECOPD. In analyses of COPD-
related hospitalizations, pneumonic AECOPD in Denmark 
accounted for 36.1% of all first-time hospitalizations for 
AECOPD and resulted in more ICU admissions (12.5% vs 
7.7%), longer median hospitalization stay (9 vs 5 days), and 
higher 30-day mortality (12% vs 8%) than nonpneumonic 
AECOPD (Figure 2A–C).25,26 The severity of pneumonic 
AECOPD is further substantiated by a UK study that found 
in-hospital mortality and 90-day mortality to be significantly 
higher in patients with pneumonic AECOPD compared to 
patients with nonpneumonic AECOPD (Figure 2D)27 and by 
a Serbian study that found pneumonia to be the second-most 
frequent autopsy-confirmed cause of death (28%) after heart 
failure (37%) in COPD patients who died within 24 hours 
of hospital admission.28
Pneumonia not only bodes poorly for the outcome of 
COPD patients but also has profound implications for health-
care systems. Direct medical costs and productivity costs 
associated with hospitalization for CAP are twice as high in 
patients with COPD compared to those in patients with no 
comorbidity.29 COPD patients with CAP are also ninefold 
more likely to be hospitalized and fourfold more likely to 
visit the ER, both of which drive the first-year health-care 
costs for these patients to an excess of US$22,348 over the 
costs of COPD patients without CAP.6 Excess costs in COPD 
patients with CAP also remain high over the second year after 
hospitalization and have been estimated to be $6,000.7
In summary, the global burden of COPD is substantial, 
and the risk and frequency of pneumococcal pneumonia 
in these patients, as well as in others with multiple comor-
bidities, is many times higher than in healthy adults without 
comorbidities. Viral and bacterial pneumonic infections are 
a major cause of respiratory events in COPD patients. The 
outcomes of these infections tend to be more severe and 
more deadly than in COPD patients with nonpneumonic 
AECOPD, leading to longer, more expensive hospitalizations 
and greater overall costs. Preventing pneumonia in COPD 
patients could provide substantial benefits to these patients, 
as well as to the community.
Pneumococcal vaccines: clinical 
evidence of efficacy and 
recommendations
Multivalent pneumococcal polysaccharide vaccines (PPVs) 
have existed for many years, and the 23-valent vaccine 
(PPV23) is recommended by many public health agencies 
for adults 65 years of age and other high-risk groups. 
Its use comes with possible caveats, however, because the 
immunoresponses to PPV23 tend to wane over time, and 
demonstrations of clinical efficacy against CAP and IPD in 
at-risk populations have been inconsistent.30–32
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However, in a recently updated Cochrane meta-analysis 
published after our symposium, pneumococcal vaccination 
(primarily with PPV23) was associated with statistically 
significant efficacy against CAP and AECOPD in COPD 
patients.33 In contrast, another recent review found the 
evidence for the clinical efficacy of PPV23 in high-risk 
and at-risk populations to be inconsistent, despite some 
short-term protection.34 In view of the historically uncertain 
and variable clinical efficacy of PPV23, the World Health 
Organization and public health agencies in Europe and the 
US recognize that there remains an unmet medical need to 
protect older adults and high-risk groups against pneumo-
coccal pneumonia.35–38
Overall, PCVs tend to be more consistently immuno-
genic than PPVs and to increase the duration and memory 
of antipneumococcal immunoresponses. Vaccination with 
Figure 2 Intensive care unit (ICU) admissions, stays, and mortality of COPD patients with pneumonic and nonpneumonic exacerbations.
Notes: (A) Admission rates among 52,520 patients with a first-time hospitalization for acute COPD exacerbation (AECOPD), 40 years of age in Denmark, 2006–2012. 
The Danish National Patient Registry was used to identify all first-time inpatient hospitalizations for pneumonic AECOPD (pAECOPD; 18,968 patients) and nonpneumonic 
AeCOPD (npAeCOPD; 33,552 patients). All COPD hospitalizations were categorized according to whether they included a primary or secondary diagnosis of pneumonia. 
Data from Søgaard et al.26 (B) Median ICU length of stay (LOS) in COPD patients due to pAeCOPD or npAeCOPD. Data were obtained from a retrospective analysis 
of all hospitalizations in 2005 in the departments of internal and respiratory medicine in one Swedish and two Norwegian hospitals. A total of 1,144 hospital admissions 
(731 patients) were identified from the patient administrative systems: 237 were for pAECOPD (mean age 75.3 years) and 472 for npAECOPD (mean age 71.7 years). 
*P0.001. Data from Andreassen et al.25 (C) 30-Day mortality among the 52,520 patients described in A, with adjustments for age, sex, comorbidity, and respiratory 
medications. Data from Søgaard et al.26 (D) In-hospital and 90-day mortality in COPD patients following hospitalization for npAeCOPD or pAeCOPD in the UK in 2008. 
UK National COPD audit data were used to determine in-hospital and 90-day mortality rates of patients admitted with npAeCOPD (542 of 7,833 patients and 951 of 7,504 
patients, respectively) or pAeCOPD (160 of 1,505 patients and 247 of 1,441 patients, respectively). A total of 9,338 admissions were assessed, with a mean age of 73 years. 
*P0.001. Data from Myint et al.27
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PPV produces an immunoresponse that is limited to B-cell 
stimulation and antibody production.39,40 In contrast, PCVs 
contain pneumococcal polysaccharide antigens covalently 
linked to an immunogenic carrier protein that together induce 
T-cell-dependent humoral immunoresponses (Figure 3) and 
stimulate T cells to help B cells produce antibodies to the 
vaccine and generate immune memory.40–43 These charac-
teristics can improve the magnitude and duration of the 
initial immunoresponse and potentially allow the immune 
system to respond more effectively to subsequent exposure 
to vaccine-type (VT) pneumococcal strains. In studies that 
have compared humoral immunoresponses to PCV and PPV 
in normal vaccine-naïve adults or older adults, short-term 
immunoglobulin and functional antibody responses were 
generally superior with PCV.40,44–46 This has also been dem-
onstrated in COPD patients, in whom superior functional 
antibody responses persisted for at least 2 years.47,48 In some 
studies, however, the in vitro B-cell-specific responses of 
older adults vaccinated with PCV or PPV23 did not dif-
fer significantly immediately after vaccination49,50 or after 
6 months.45 In healthy adults, long-term immunoresponses 
with PPV23 remain above baseline for as long as 10 years, 
though booster immunizations are generally recommended 
after 5 years.51 To our knowledge, the long-term immunoge-
nicity of PCV in normal healthy adults beyond 2 years has not 
been reported, but significant immunoresponses are known 
to persist for up to 5 years in HIV-positive adults.52
PCVs are recommended for all children and have been 
shown to prevent nasopharyngeal carriage of VT strains and 
to protect children against mucosal diseases, IPD, and otitis 
media.53–57 Childhood vaccination programs that include PCV 
have also demonstrated significant reductions in pneumococ-
cal diseases in adults (herd protection) as an indirect conse-
quence of lower pneumococcal carriage in children.58,59
CAPITA was conducted to assess the clinical efficacy of 
PCV13 in older adults. It was a large prospective randomized, 
placebo-controlled trial in 84,000 participants 65 years 
of age.8 The primary outcome was the efficacy of preventing 
a first episode of VT CAP. With up to 5 years of follow-up, 
vaccine efficacy in the per-protocol population was 45.6% 
against VT CAP and 45% against abacteremic, nonin-
vasive VT CAP (Figure 4). Vaccine efficacy was 30.6% 
against pneumococcal CAP and 75% against VT IPD. In an 
exploratory post hoc analysis of the at-risk population in the 
study, which included over 42% of the participants in each 
group, 10% of which had lung disease, vaccine efficacy was 
similar: 40.3% against VT CAP and 30.2% against pneu-
mococcal CAP.97 Furthermore, the magnitude and duration 
of humoral immunoresponses in at-risk adults assessed by 
opsonophagocytic assay geometric mean antibody titers were 
3RO\VDFFKDULGHDQWLJHQ
3RO\VDFFKDULGHYDFFLQHV
&RQWDLQSRO\VDFFKDULGHDQWLJHQV &RQWDLQSRO\VDFFKDULGHDQWLJHQVFRYDOHQWO\OLQNHGWRDFDUULHUSURWHLQ
7FHOOLQGHSHQGHQWLPPXQRUHVSRQVH
6WLPXODWH%FHOOVWRSURGXFHDQWLERGLHV
7FHOOGHSHQGHQWLPPXQRUHVSRQVH
6WLPXODWH7FHOOVWRKHOS%FHOOVSURGXFHDQWLERGLHVDQGJHQHUDWHLPPXQHPHPRU\3URYLGHLPSURYHGLPPXQRORJLFDOUHVSRQVHV3UHYHQWQDVRSKDU\QJHDOFDUULDJH
&RQMXJDWHYDFFLQHV
3RO\VDFFKDULGHDQWLJHQ &DUULHUSURWHLQ
$QWLERGLHV
%FHOOV 7FHOOV %FHOOV
0DWXUDWLRQRI%FHOOUHVSRQVH6LJQDOV
Figure 3 Immunogenic effects of pneumococcal vaccines.
Notes: Pneumococcal polysaccharide vaccines contain serotype-specific polysaccharide antigens only and induce T-cell-independent antibody production from B cells. 
These responses tend to wane over time. Pneumococcal conjugate vaccines contain serotype-specific polysaccharide antigens covalently linked to a carrier protein. These 
vaccines induce T-cell-dependent antibody production from B cells and improve immune memory, allowing antipneumococcal immunoresponses to be generated long after 
vaccination. Based on data from Clutterbuck et al,41 de Roux et al,40 Pollard et al,42 and Siegrist.43
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comparable to those of the overall population and persisted 
for at least 2 years.60
Finally, another post hoc analysis predicted that vaccine 
efficacy would decline from 65% for adults 65 years of age 
to 40% for adults 75 years of age, suggesting that patients 
with indications of PCV should be vaccinated as early as 
possible.61 While these results are encouraging, post hoc 
analyses should be viewed with caution, and the efficacy of 
PCV13 for preventing VT CAP in CRD patients has yet to 
be demonstrated in a randomized clinical trial designed to 
address this issue specifically. It should be noted that in such 
a hypothetical trial, the necessary sample size to demonstrate 
efficacy is likely to be very large, and recruiting the mini-
mum number of CRD patients for the treatment and control 
arms would be extremely difficult, especially in the context 
of populations benefiting from herd immunity arising from 
pediatric vaccination programs.
Recently published studies have also investigated the 
efficacy of PPV23 in older adults. A meta-analysis of 
17 eligible studies in adults 60 years of age found pooled 
efficacies of PPV23 against IPD (45%−73%) and pneumo-
coccal pneumonia (48%−64%) by any serotype.62 Another 
meta-analysis of studies in adults 50 years of age also found 
evidence of significant vaccine efficacy for PPV23 against 
IPD (50%−54%) and against all-cause CAP (4%−17%).63 
Both studies concluded that efficacies of PPV23 and PCV13 
against VT pneumococcal disease were comparable. In a mul-
ticenter prospective study in adults 65 years of age treated 
for CAP, PPV23 efficacy was 27.4% (95% CI: 3.2%–45.6%) 
against all pneumococcal pneumonia.64
The US Advisory Committee on Immunization Practices 
currently recommends PCV13 followed by PPV23 for all 
adults 65 years of age who have not previously received 
pneumococcal vaccine and in persons 19 years of age who 
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Figure 4 Efficacy of PCV13 in older adults: results of the CAPITA study.
Notes: CAPITA was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy of 13-valent polysaccharide conjugate vaccine (PCV13) versus placebo in 
84,496 adults 65 years of age. The primary objective was vaccine efficacy in preventing a first episode of vaccine-type pneumococcal community-acquired pneumonia (CAP). 
A secondary objective was vaccine efficacy in preventing a first episode of vaccine-type abacteremic (AB) and noninvasive (NI) pneumococcal CAP. The figure illustrates post 
hoc analyses of the cumulative episodes of primary and secondary efficacy end points in the per-protocol population. (A) Cumulative first episodes of vaccine-type CAP from 
vaccination to 5-year follow-up. Vaccine efficacy was 45.6% (95.2% CI: 21.8%–62.5%, P0.001). (B) Cumulative first episodes of vaccine-type AB and NI CAP from vaccination 
to 5-year follow-up. Vaccine efficacy was 45% (95.2% CI: 14.2%–65.3%, P=0.007). (C) Cumulative first episodes of vaccine-type invasive pneumococcal disease (IPD) from 
vaccination to 5-year follow-up. Vaccine efficacy was 75% (95% CI: 41.4%–90.8%, P0.001). From N Engl J Med. Bonten et al. Polysaccharide conjugate vaccine against 
pneumococcal pneumonia in adults. 372:1114–1125. Copyright © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.8
Abbreviation: CAPITA, Community-Acquired Pneumonia Immunization Trial in Adults.
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are at high risk of pneumococcal disease due to underlying 
medical conditions.65,66 Several European scientific societies 
also recommend PCV13 for immunocompromised adults and 
all persons 65 years of age, along with at least one dose of 
PPV23 given 2−6 months afterward.67 PCV13 is now being 
progressively implemented into national programs across 
Europe. As of August 2016, PCV13 is recommended for use 
in high-risk populations in 25 countries, for use in at-risk 
populations in 16 countries, and for use in older adults 
(50 or 65 years of age) in 14 countries.
PCV13 is recommended to be given before PPV23.66 This 
schedule is based on the observation that the responses to the 
serotypes common to both vaccines were stronger if PCV13 
were administered first.68 Of note, PCV13 can be given 
concomitantly with a seasonal inactivated influenza vaccine 
without impacting immunoresponses to either vaccine, which 
can help avoid missed opportunities for vaccination.69,70
In summary, PCV13 has been developed to provide 
improved protection for older adults and adults with chronic 
conditions, such as COPD, who are at high risk of pneumococ-
cal infection and pneumonia. In the pivotal CAPITA study, 
PCV13 induced specific and efficacious immunoresponses in 
adults 65 years of age with or without underlying chronic 
conditions that elevate the risk of pneumonia, and vaccine effi-
cacy against VT CAP and VT IPD persisted for up to 5 years. 
As a result, an increasing number of countries across Europe 
are including PCV13 in their vaccination recommendations.
Role of pneumococcal vaccination 
in patients with chronic respiratory 
diseases
Current European Respiratory Society and European Society of 
Clinical Microbiology and Infectious Diseases guidelines were 
published before the recent results on PCV, and thus recom-
mended only PPV23 for older adults and adults with risk factors 
for pneumococcal disease, such as age 65 years, congestive 
heart failure, COPD, and a previous history of pneumonia.71 
Specific recommendations on pneumococcal vaccination are 
lacking in many guidelines on CRDs from international societ-
ies. For COPD, pneumococcal vaccination is recommended 
in current GOLD guidelines, which mention the increased 
immunogenicity of PCV13, but do not propose a clear position 
on whether it should be preferred over PPV23.72
Because LRTIs are an important trigger for exacerbations, 
preventing them in COPD patients could also help prevent 
exacerbations.5 Early prevention of exacerbations may also 
be critically important for preventing disease progression and 
subsequent events, as exacerbations can indicate or precede a 
feed-forward pattern of increased susceptibility to exacerbation 
and in some cases a frequent exacerbation phenotype.21 In the 
natural history of COPD, each exacerbation is associated with 
an increased risk of subsequent exacerbations, which tend to 
occur with greater frequency and severity. It is well known that 
patients can enter a vicious cycle of infection, exacerbation, 
and disease progression.3,4,73,74 With each exacerbation, further 
tissue destruction and functional impairment can occur along 
with worsening mucociliary clearance and increased bacterial 
colonization, all of which increase the risk of developing an 
LRTI and another exacerbation. The reality of this concept 
was further demonstrated by comparing the exacerbation 
frequencies of COPD patients after a CAP episode to those in 
COPD patients who had not had CAP (Figure 5). The cumula-
tive risk of exacerbation in the first year after CAP was 1.5 
times higher in patients who had had CAP (17%) compared 
to those who had not (11.4%; P0.001).96
Clinical evidence of pneumococcal 
vaccine efficacy in COPD
In principle, pneumococcal vaccination should prevent 
LRTI and acute exacerbations in COPD patients, but inter-
preting the existing evidence for the clinical efficacy of PPV 
in these high-risk patients has been somewhat problematic. 
In a 2010 Cochrane systematic review and meta-analysis of 
seven studies,32 the overall vaccine effect against pneumonia 
was of borderline significance compared to placebo, with an 
OR of 0.72 (95% CI: 0.51–1.01), with no significant effects 
on either exacerbations or cardiorespiratory mortality. While 
these results suggested that PPV may confer some protection 
in COPD patients, the lack of statistical significance for any 
outcome and the heterogeneity of the studies rendered the 
evidence inconclusive. The evidence for vaccine efficacy 
improved somewhat in the 2017 update of this Cochrane 
review, which included a reanalysis of the same studies used 
in the 2010 meta-analysis of pneumococcal vaccination 
efficacy (primarily PPV23) against CAP, and concluded 
that vaccination was associated with significant reductions 
in the likelihood of experiencing CAP (OR: 0.62, 95% CI: 
0.43–0.89) or AECOPD (OR: 0.6, 95% CI: 0.39–0.9).33
A recent review of pneumococcal vaccine efficacy studies 
in persons with underlying risk factors, such as COPD or a 
CRD, vaccine efficacy against any-cause CAP was found to 
vary widely between −338% and 43%, with an overall effi-
cacy of 29% (95% CI: −39%–63%) in adults aged 50 years 
with CRD.34 In a randomized controlled trial in 596 COPD 
patients, PPV23 efficacy against CAP was significant at 
76% (95% CI: 20–93, P=0.013) in patients 65 years of 
age, nearly significant at 48% (95% CI: 27–80, P=0.076) 
in those with severe airflow obstruction (40% FEV
1
), and 
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strongest for both factors combined (91% [95% CI: 35–99, 
P=0.002]).75 However, vaccine efficacy was not significant 
for the overall cohort (24% [95% CI: −24–54, P=0.333]).
In a study of the combined efficacy of PPV23 and influ-
enza vaccination in preventing acute exacerbation in adult 
CRD patients, acute exacerbation frequency was significantly 
lower in the PPV23 + influenza vaccination group than in 
the influenza vaccination-alone group (P=0.022), and there 
was a significant additive effect of PPV23 in COPD patients 
(P=0.037).76 In view of the limited numbers of studies avail-
able to date, the evidence on the role of PPV for protecting 
COPD patients from CAP can be considered inconsistent.
In contrast, seasonal influenza vaccine has demonstrated 
significant efficacy in preventing exacerbations in COPD 
patients compared to placebo, with a reported weighted 
mean difference between treatments of −0.37 (95% CI: −0.64 
to −0.11, P=0.006) in a meta-analysis of two randomized 
trials.77 If influenza vaccine is administered concomitantly 
with PPV23, the two vaccines provide an additive effect in 
reducing the risk of hospitalization for pneumonia, death, 
death from influenza, and death from pneumonia.78–80
Another potential benefit of an effective pneumococcal 
vaccination could be a reduction in antibiotic treatments. 
This has not been studied in COPD patients, but has been 
estimated in children by comparing antibiotic treatment days 
for S. pneumoniae infections in countries with high childhood 
PCV coverage versus countries without such coverage.81 
Globally, an estimated 11.4 million antibiotic treatment days 
were avoided in countries with PCV coverage, a reduction 
of 47%. Reducing antibiotic treatment in COPD patients 
could also help delay or prevent colonization of the lungs 
by antibiotic resistant bacteria.
Real-life vaccine coverage of the target 
population
Despite the availability of effective pneumococcal vac-
cines and recommendations from most national health 
authorities, coverage remains suboptimal in many settings. 
Recent coverage rates have been fairly high in the UK 
(70% in persons 65 years of age in 2014−2015) and in 
Spain (76% in persons 60 years of age in 2010), lower in 
Ireland (36% in persons 65 years of age and 18% in high-
risk adults in 2013), and very low in Norway (15%−30% 
in persons 65 years of age in 2014−2015), Germany 
(15% in high-risk persons in 2014), and France (~5% in 
persons 65 years of age in 2010−2011).82–87
Figure 5 Community-acquired pneumonia (CAP) and occurrence of subsequent exacerbations in COPD patients in the US, 2010.
Notes: In a retrospective cohort study of 12,327 matched pairs, CAP patients aged 18 years who had continuous and comprehensive health benefits, evidence of COPD, 
and no evidence of pneumonia during the preceding year were identified between January and December 2010. One comparison patient from the corresponding source 
population who had continuous and comprehensive health benefits, evidence of COPD, and no evidence of pneumonia during the preceding year was matched with each CAP 
patient on the date of the initial CAP encounter (or inpatient admission date) or within the next 30 days. Comparison patients were also matched with each CAP patient on 
age (±1 year), sex, and selected markers of health status measured in the preceding year. Exacerbation was defined as a hospitalization or emergency department visit during 
follow-up, which began 30 days after pneumonia diagnosis and ended 12 months later. *P0.001. From weycker et al;96 reprinted with permission from the authors.
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An indication of the reasons behind these suboptimal 
coverage rates may lie in the perceptions and vaccine aware-
ness of older adults. A recent survey (PneuVUE, Pfizer, Paris, 
France) measured public awareness of pneumonia and vac-
cine perceptions in adults 50 years of age across nine EU 
countries.88 The survey found that 85% of these adults trusted 
vaccines, 27% avoided vaccines (for safety reasons), and 29% 
feel they “didn’t need” vaccines because they were not at 
risk. However, high proportions of respondents reported that 
they did follow their physician’s advice (92%) and that they 
preferred to obtain additional medical information from their 
doctor (92%). Overall, pneumococcal vaccine awareness was 
low, and the most frequent reason given (55%) for not being 
vaccinated was that it was never offered by their doctor.
To summarize, evidence-based guidelines recommend 
pneumococcal vaccination in persons with CRD, and PCV13 
has already been included in a number of national recommen-
dations, including those in the US, France, Portugal, Spain, 
Italy, and others.66,89–92 Some countries, such as Germany 
and the UK, continue to consider the evidence and favor 
the broader serotype coverage of PPV23.93,94 In patients 
with COPD, preventing LRTIs, which frequently involve 
S. pneumoniae, appears critical, because they can alter dis-
ease status and speed disease progression, thus increasing 
the risk of subsequent exacerbation. Including pneumococ-
cal vaccination in early care for COPD may improve the 
long-term natural history of the disease, although further 
evidence is needed. Despite recommendations, overall pneu-
mococcal vaccination coverage is poor across Europe and 
public awareness and knowledge of pneumococcal disease 
and vaccines is low. Since patients rely on their physicians 
as the main source of health information, physicians need 
to do a better job of informing their at-risk patients about 
the dangers of pneumonia and the benefits of pneumococcal 
vaccination.
Conclusion
Global CRD burdens are high and contribute to substantial 
excess health-care use, hospitalizations, and global morbidity 
and mortality.72 Patients with COPD and other CRDs are 
at high risk of CAP, IPD, and exacerbations that further 
increase health-care burdens and mortality.12,13 In COPD, 
airway infections are important triggers of exacerbations 
and hasten disease progression. There is evidence for the 
efficacy of PPV23 in older adults,62,63 but evidence for pro-
tection in CRD patients has been considered inconclusive.32 
The CAPITA study provided clinical evidence that PCV13 
is effective at preventing CAP in older adults, including 
those with comorbidities.8 Post hoc analyses of CAPITA 
are consistent with PCV13 efficacy in patients with comor-
bidities, but these results should be viewed with caution. 
Indeed, vaccine efficacy in adults is likely to vary according 
to the pneumococcal vaccines used in pediatric vaccination 
programs and efficacy may be low or difficult to demon-
strate in settings where pediatric uptake of pneumococcal 
vaccine is high and the consequent burden of disease in 
adults is reduced.95 However, given the substantially higher 
risk of respiratory infection and dire consequences of such 
infections in patients with COPD or CRD, vaccination is 
warranted in these patients, regardless of the level of herd 
protection present in the community.
Influenza and pneumococcal infections are important con-
tributors to CAP and acute exacerbations in COPD patients, 
and pneumococcal and influenza vaccinations together may 
have an additive preventive effect.78–80 Vaccination early in 
the course of COPD could help maintain stable health status, 
although further demonstration is needed.5,21 Despite the great 
burden of pneumonia and pneumococcal infection, the need 
for vaccination in patients with CRD–COPD, the evidence on 
pneumococcal vaccine efficacy, and widespread national rec-
ommendations, improvements are needed in pneumococcal 
vaccine coverage, knowledge, and awareness.88 As the main 
source of medical information for the public, physicians need 
to communicate more effectively the benefits of vaccination 
with PCV to their patients, especially those with CRDs.
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